These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 34093633)

  • 21. Key considerations for comprehensive validation of an RNA fusion NGS panel.
    Barua S; Wang G; Mansukhani M; Hsiao S; Fernandes H
    Pract Lab Med; 2020 Aug; 21():e00173. PubMed ID: 32613069
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical Validation of a Next-Generation Sequencing Genomic Oncology Panel via Cross-Platform Benchmarking against Established Amplicon Sequencing Assays.
    Kadri S; Long BC; Mujacic I; Zhen CJ; Wurst MN; Sharma S; McDonald N; Niu N; Benhamed S; Tuteja JH; Seiwert TY; White KP; McNerney ME; Fitzpatrick C; Wang YL; Furtado LV; Segal JP
    J Mol Diagn; 2017 Jan; 19(1):43-56. PubMed ID: 27836695
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeted Next Generation Sequencing as a Reliable Diagnostic Assay for the Detection of Somatic Mutations in Tumours Using Minimal DNA Amounts from Formalin Fixed Paraffin Embedded Material.
    de Leng WW; Gadellaa-van Hooijdonk CG; Barendregt-Smouter FA; Koudijs MJ; Nijman I; Hinrichs JW; Cuppen E; van Lieshout S; Loberg RD; de Jonge M; Voest EE; de Weger RA; Steeghs N; Langenberg MH; Sleijfer S; Willems SM; Lolkema MP
    PLoS One; 2016; 11(2):e0149405. PubMed ID: 26919633
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quality metrics for enhanced performance of an NGS panel using single-vial amplification technology.
    Barua S; Hsiao S; Clancy E; Freeman C; Mansukhani M; Fernandes H
    J Clin Pathol; 2023 Dec; 77(1):46-53. PubMed ID: 36376073
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development and Analytical Validation of a Targeted Next-Generation Sequencing Panel to Detect Actionable Mutations for Targeted Therapy.
    Wang D; Ma K; Deng W; Li J; Xiang S; Zhang Y; Fu Y; Dai H; Huang B
    Onco Targets Ther; 2021; 14():2423-2431. PubMed ID: 33854338
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analytical Validation of an Automated Semiconductor-Based Next-Generation Sequencing Assay for Detection of DNA and RNA Alterations in Myeloid Neoplasms.
    Zbieranski N; Insuasti-Beltran G
    J Mol Diagn; 2024 Jan; 26(1):29-36. PubMed ID: 37879438
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development and validation of the JAX Cancer Treatment Profile™ for detection of clinically actionable mutations in solid tumors.
    Ananda G; Mockus S; Lundquist M; Spotlow V; Simons A; Mitchell T; Stafford G; Philip V; Stearns T; Srivastava A; Barter M; Rowe L; Malcolm J; Bult C; Karuturi RK; Rasmussen K; Hinerfeld D
    Exp Mol Pathol; 2015 Feb; 98(1):106-12. PubMed ID: 25562415
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Integration of Technical, Bioinformatic, and Variant Assessment Approaches in the Validation of a Targeted Next-Generation Sequencing Panel for Myeloid Malignancies.
    Thomas M; Sukhai MA; Zhang T; Dolatshahi R; Harbi D; Garg S; Misyura M; Pugh T; Stockley TL; Kamel-Reid S
    Arch Pathol Lab Med; 2017 Jun; 141(6):759-775. PubMed ID: 28557600
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multicenter validation of cancer gene panel-based next-generation sequencing for translational research and molecular diagnostics.
    Hirsch B; Endris V; Lassmann S; Weichert W; Pfarr N; Schirmacher P; Kovaleva V; Werner M; Bonzheim I; Fend F; Sperveslage J; Kaulich K; Zacher A; Reifenberger G; Köhrer K; Stepanow S; Lerke S; Mayr T; Aust DE; Baretton G; Weidner S; Jung A; Kirchner T; Hansmann ML; Burbat L; von der Wall E; Dietel M; Hummel M
    Virchows Arch; 2018 Apr; 472(4):557-565. PubMed ID: 29374318
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Validation of a next-generation sequencing oncology panel optimized for low input DNA.
    Sussman RT; Shaffer S; Azzato EM; DeSloover D; Farooqi MS; Meyer A; Lieberman DB; Bigdeli A; Paolillo C; Ganapathy K; Sukhadia S; Rosenbaum JN; Daber RD; Morrissette JJD
    Cancer Genet; 2018 Dec; 228-229():55-63. PubMed ID: 30553474
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The differential diagnoses of uterine leiomyomas and leiomyosarcomas using DNA and RNA sequencing.
    Mas A; Alonso R; Garrido-Gómez T; Escorcia P; Montero B; Jiménez-Almazán J; Martín J; Pellicer N; Monleón J; Simón C
    Am J Obstet Gynecol; 2019 Oct; 221(4):320.e1-320.e23. PubMed ID: 31121144
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical validation of the Ion Torrent Oncomine Myeloid Assay GX v2 on the Genexus Integrated Sequencer as a stand-alone assay for single-nucleotide variants, insertions/deletions, and fusion genes: Challenges, performance, and perspectives.
    Krishnamurthy K; Chai J; Liu X; Wang Y; Naeem R; Goldstein DY
    Am J Clin Pathol; 2024 Jun; ():. PubMed ID: 38823030
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development and validation of an ultra-high sensitive next-generation sequencing assay for molecular diagnosis of clinical oncology.
    Liang J; She Y; Zhu J; Wei L; Zhang L; Gao L; Wang Y; Xing J; Guo Y; Meng X; Li P
    Int J Oncol; 2016 Nov; 49(5):2088-2104. PubMed ID: 27826616
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeted next-generation sequencing panel (TruSight Tumor 170) in diffuse glioma: a single institutional experience of 135 cases.
    Na K; Kim HS; Shim HS; Chang JH; Kang SG; Kim SH
    J Neurooncol; 2019 May; 142(3):445-454. PubMed ID: 30710203
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
    Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
    Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Validation of quantitative PCR-based assays for detection of gene copy number aberrations in formalin-fixed, paraffin embedded solid tumor samples.
    Mehrotra M; Luthra R; Abraham R; Mishra BM; Virani S; Chen H; Routbort MJ; Patel KP; Medeiros LJ; Singh RR
    Cancer Genet; 2017 Apr; 212-213():24-31. PubMed ID: 28449808
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Single-Center Experience with a Targeted Next Generation Sequencing Assay for Assessment of Relevant Somatic Alterations in Solid Tumors.
    Paasinen-Sohns A; Koelzer VH; Frank A; Schafroth J; Gisler A; Sachs M; Graber A; Rothschild SI; Wicki A; Cathomas G; Mertz KD
    Neoplasia; 2017 Mar; 19(3):196-206. PubMed ID: 28161563
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Accuracy and reproducibility of somatic point mutation calling in clinical-type targeted sequencing data.
    Karimnezhad A; Palidwor GA; Thavorn K; Stewart DJ; Campbell PA; Lo B; Perkins TJ
    BMC Med Genomics; 2020 Oct; 13(1):156. PubMed ID: 33059707
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development and Validation of a Next-Generation Sequencing Assay for BRCA1 and BRCA2 Variants for the Clinical Laboratory.
    Strom CM; Rivera S; Elzinga C; Angeloni T; Rosenthal SH; Goos-Root D; Siaw M; Platt J; Braastadt C; Cheng L; Ross D; Sun W
    PLoS One; 2015; 10(8):e0136419. PubMed ID: 26295337
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies.
    Houghton J; Hadd AG; Zeigler R; Haynes BC; Latham GJ
    J Vis Exp; 2016 Apr; (110):e53836. PubMed ID: 27166994
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.